UroAlerts - Prostate Cancer Weekly

November 26, 2024

Videos

Peer-to-Peer Clinical Conversations

Understanding Time Toxicity: Impact of Treatment Time on Prostate Cancer Patients - Daniel Sentana Lledo

Daniel Sentana

Ruchika Talwar hosts Daniel Sentana Lledo to discuss the concept of time toxicity in prostate cancer treatment.

Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments "Presentation" - Scott Eggener

Scott Eggener

At the 2024 LUGPA annual meeting, Scott Eggener reviews cutting-edge prostate cancer technologies, from screening and imaging to genomic testing and emerging treatments.

Conference Coverage

ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer

ASTRO 2024: Role of Brachytherapy for Unfavorable Intermediate Risk Prostate Cancer

ASTRO 2024: Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials

Physician-Scientist Review Articles

ESMO 2024 Quick Take Insights: Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.

Discrimination against Gay and Bisexual Patients in Prostate Cancer Treatment: Results from the Restore-2 Study.

Prioritizing precision: detection of prostate cancer using mri guided fusion needle biopsy across the pennsylvania urologic regional collaborative.

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance.

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease.

Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer.

Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective.

Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis.

Association of Race and Area of Deprivation Index with Prostate Cancer Incidence and Lethality.

Organ-confined prostate cancer with negative surgical margins in an entirely-embedded radical prostatectomy is essentially non-lethal-a retrospective single-institutional study of 520 patients.

PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects.

Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes.

A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer.

Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA.

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.

Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer.

Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer.

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment.

Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.

Sclerotic prostate cancer bone metastasis: woven bone lesions with a twist.

Automated real-world data integration improves cancer outcome prediction.

Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.

Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.

The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.

Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.

Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.

Anatomic Factors Associated with Complications After Radical Prostatectomy: A Systematic Review and Meta-analysis.

Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.

Prostate Cancer Screening: Common Questions and Answers.

Comparing the Technological and Intraoperative Performances of Da Vinci xi and DaVinci 5 Robotic Platforms in Patients Undergoing Robotic-Assisted Radical Prostatectomy.

Preoperative prostate magnetic resonance imaging does not impact surgical outcomes of radical prostatectomy.

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer.

Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer.

A Systematic Review of the Diagnostic Accuracy of Deep Learning Models for the Automatic Detection, Localization, and Characterization of Clinically Significant Prostate Cancer on Magnetic Resonance Imaging.

Small-molecule disruption of androgen receptor-dependent chromatin clusters.

Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis.

Computational analysis of variability and uncertainty in the clinical reference on magnetic resonance imaging radiomics: modelling and performance.

Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis - Beyond the Abstract

Evaluating 4Kscore's Role in Predicting Progression on Active Surveillance for Prostate Cancer Independently of Clinical Information and PIRADS Score - Beyond the Abstract

CDK12 Loss Drives Prostate Cancer Progression, Transcription-Replication Conflicts, and Synthetic Lethality with Paralog CDK13 - Beyond the Abstract

CRPC w/ bone metastases

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compare

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC